Related Experiment Video
Updated: Mar 13, 2026
Isolated Pancreatic Islet Treatment and Apoptosis Measurement
Published on: May 2, 2025
Experimental cannabidiol treatment reduces early pancreatic inflammation in type 1 diabetes
Christian Lehmann1,2,3,4, Nicholas B Fisher5, Barna Tugwell6
1Department of Anesthesia, Pain Management and Perioperative Medicine, Dalhousie University, Halifax, NS, Canada.
Background:
Destruction of the insulin-producing beta cells in type 1 diabetes (T1D) is induced by invasion of immune cells causing pancreatic inflammation. Cannabidiol (CBD), a phytocannabinoid, derived from the plant, Cannabis sativa, was shown to lower the incidence of diabetes in non-obese diabetic (NOD) mice, an animal model of spontaneous T1D development.
Objective:
The goal of this study was to investigate the impact of experimental CBD treatment on early pancreatic inflammation in T1D by intravital microscopy (IVM) in NOD mice.
Methods:
Seven-week-old female NOD mice were prophylactically administered daily 5 mg/kg CBD or control vehicle i.p. five times weekly for ten weeks. Animals underwent IVM following confirmation of T1D diagnosis by blood glucose testing. Leukocyte activation and functional capillary density (FCD) were quantified via IVM.
Results:
CBD-treated NOD mice developed T1D later and showed significantly reduced leukocyte activation and increased FCD in the pancreatic microcirculation.
Conclusions:
Experimental CBD treatment reduced markers of inflammation in the microcirculation of the pancreas studied by intravital microscopy.
Insights
Cannabidiol (CBD) may protect against type 1 diabetes (T1D) by reducing pancreatic inflammation and improving blood vessel function in mice. This study explored CBD's anti-inflammatory effects in a T1D animal model.
Area of Science:
- Immunology
- Endocrinology
- Pharmacology
Background:
- Type 1 diabetes (T1D) involves immune cell destruction of pancreatic beta cells, leading to inflammation.
- Cannabidiol (CBD), a Cannabis sativa phytocannabinoid, has shown potential in reducing diabetes incidence in non-obese diabetic (NOD) mice.
Purpose of the Study:
- To investigate the therapeutic effects of experimental Cannabidiol (CBD) treatment on early pancreatic inflammation in a type 1 diabetes (T1D) model.
- To assess CBD's impact on leukocyte activation and functional capillary density (FCD) in the pancreatic microcirculation of NOD mice using intravital microscopy (IVM).
Main Methods:
- Female NOD mice received daily prophylactic CBD (5 mg/kg) or vehicle control for ten weeks.
- Intravital microscopy (IVM) was employed to quantify leukocyte activation and functional capillary density (FCD) in the pancreas post-T1D diagnosis.
- Blood glucose levels were monitored to confirm T1D diagnosis.
Main Results:
- CBD-treated NOD mice exhibited delayed T1D onset compared to controls.
- Significant reductions in leukocyte activation were observed in the pancreatic microcirculation of CBD-treated mice.
- Increased functional capillary density (FCD) was noted in the pancreas of NOD mice receiving CBD treatment.
Conclusions:
- Experimental Cannabidiol (CBD) administration demonstrated a reduction in pancreatic microcirculation inflammation markers.
- CBD treatment positively influenced leukocyte activation and functional capillary density (FCD) in a preclinical model of type 1 diabetes.
- These findings suggest CBD's potential as an anti-inflammatory agent in T1D management.
Related Concept Videos
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:15Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...